Please assess the completion status of the following clinical trial:

Trial Title: Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years or older~2. Diagnosis of primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF~3. Enlarged spleen, measuring 5 cm or greater from the costal margin~4. Must have two or more of the following risk factors:~   1. Over 65 years old~  2. Have the following symptoms often associated with MF: loss of weight, fever, night sweats~  3. Have a low red blood cell count (anemia - hemoglobin \< 10 g/dL)~  4. Have a high white blood cell count (history of white blood cell count \> 25,000/uL)~  5. Have high circulating blasts (\> or = 1%) as measured by blood tests~5. Should have circulating blasts \<10% (as measured by blood tests)~6. Should be capable of self-care~7. Should have adequate bone marrow reserve~8. Should not have the option of stem cell transplantation~9. Should discontinue any prior or ongoing treatment for myelofibrosis prior to entering the study~10. Had no prior treatment with another JAK inhibitor~Exclusion Criteria:~1. Does not have adequate liver or kidney function (as measured by blood tests)~2. Has an active infection (bacterial, viral, etc.)~3. Has active hepatitis A, B, or C or positive for HIV~4. Has another cancer that needs active intervention~5. Had a history of bleeding disorder~6. Had a history of very low platelet counts (as measured by blood tests) not related to treatment of MF~7. Had radiation of the spleen within 1 year of joining the study~8. Does not have adequate heart function~9. Sufficient time has elapsed between stopping previous treatment for MF and joining the study~10. Females who are pregnant or breast-feeding~11. Not able to sign informed consent~12. Has any other active medical conditions that the doctor deems may compromise your safety or ability to join in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib (Type: EXPERIMENTAL): Ruxolitinib was taken twice daily, unless instructed. Starting dose 15 mg BID for patients with baseline platelet count of 100,000/μL to 200,000/μL (inclusive) or 20 mg BID for those with baseline platelet count \>200,000/μL (approximately 12 hours apart: morning and night), increased or decreased per standardized dosing paradigm.

Based on this trial design, predict the completion outcome and termination type (if applicable).